Syngene International Limited
HSBC Mutual Fund initiated a new position in Syngene International with 62,38,897 shares, representing a 1.55% stake worth ₹260.42 Cr at a share price of ₹417.45.
India's first Contract Research Organization, Syngene provides integrated drug discovery, development, and manufacturing services through a single platform known as CRAMS. Established in 1993 as a Biocon subsidiary, the company operates extensive research and manufacturing facilities spanning multiple locations across the country. It serves global pharmaceutical and biotechnology clients with end-to-end solutions, from early-stage research through commercial-scale production.
Indian arm of HSBC Asset Management, the investment arm of HSBC Group with over USD 600 billion in global AUM. Manages over Rs 1 lakh crore in India across equity, debt and hybrid schemes. Previously known for integration of L&T Mutual Fund schemes after acquiring it from L&T Finance in 2022, which significantly expanded the franchise.